EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Economic impact of RSV prefusion F protein-based (RSVpreF) vaccination and nirsevimab prophylaxis on RSV-associated disease among Japanese infants

Shu-Ling Hoshi, Xerxes Seposo, Masahide Kondo

Value in Health · 2026

DOI: 10.1016/j.jval.2026.01.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2026. Verfasst von Shu-Ling Hoshi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Care Policy and Health Economics, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. Electronic address: shu…. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Antiviral Agents, Antibodies, Monoclonal, Humanized. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Government of Japan Ministry of Health Labour and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Respiratory syncytial virus is known to cause severe bronchiolitis and pneumonia among infants. There are 2 main ways to protect infants from respiratory syncytial virus (RSV)-related diseases, namely, vaccination of pregnant women with recombinant subunit RSV pre-fusion F3 (RSVpreF) and prophylaxis of neonates/infants with nirsevimab. In 2024, both products were approved in Japan. We evaluated the cost-effectiveness of multiple immunization strategies for the protection of Japanese infants from RSV diseases by using nirsevimab and/or RSVpreF. METHODS: A decision tree with Markov model was adopted. Incremental cost-effectiveness ratio (ICER) from payers' perspective was calculated. Variables used in the model were either calculated or extracted from literature. Costs per RSVpreF and nirsevimab vaccination was assumed to be at JPY23 948/US$160 and JPY45 000/US$300, respectively. RESULTS: Vaccination of pregnant women with RSVpreF strategies (seasonally or year-round), prophylaxis of infants with the nirsevimab strategy, and a combination of seasonally RSVpreF and nirsevimab strategies, all reduced disease treatment costs; however, the reduction could not offset the vaccination/prophylaxis cost. RSVpreF_year-round strategy and nirsevimab strategy were either extended or absolutely dominated by the other 2 strategies and were excluded from being considered as an option. The ICER of seasonal RSVpreF strategy was JPY3 227 850/US$21 519/quality-adjusted life-years (QALY), whereas the Combination strategy's ICER was JPY23 236 084/US$154 907/QALY per QALY gained. One-way sensitivity analyses revealed that the probability of hospitalization, vaccination costs, and effectiveness of both products influence the ICER the most. The cost-effectiveness acceptance curve revealed that the curve reached 98.7% at a willingness to pay of JPY5 000 000/US$33 333 per QALY. CONCLUSIONS: Only seasonal RSVpreF strategy is cost-effective under the JPY5 000 000/US$33 333 per QALY willingness-to-pay threshold.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesAntiviral AgentsAntibodies, Monoclonal, HumanizedViral Fusion ProteinsHumansCost-Benefit AnalysisJapanFemaleMarkov ChainsPregnancyCost-Effectiveness AnalysisInfantInfant, NewbornQuality-Adjusted Life YearsDecision TreesVaccinationEast Asian People

Stichwörter der Autor:innen

Markov modelQALYcost-utilitydecision analytic modelutility

Substanzen

Respiratory Syncytial Virus VaccinesAntiviral AgentsAntibodies, Monoclonal, HumanizedViral Fusion ProteinsF protein, human respiratory syncytial virus

Autor:innen und Institutionen

  • Department of Health Care Policy and Health Economics, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. Electronic address: shulingst2020@gmail.com.
  • Department of Hygiene, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Department of Health Care Policy and Health Economics, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.

Förderung

  • Government of Japan Ministry of Health Labour and Welfare

Zitieren

APA

Hoshi, S. L., Seposo, X., & Kondo, M. (2026). Economic impact of RSV prefusion F protein-based (RSVpreF) vaccination and nirsevimab prophylaxis on RSV-associated disease among Japanese infants. Value in Health. https://doi.org/10.1016/j.jval.2026.01.010

Vancouver

Hoshi SL, Seposo X, Kondo M. Economic impact of RSV prefusion F protein-based (RSVpreF) vaccination and nirsevimab prophylaxis on RSV-associated disease among Japanese infants. Value in Health. 2026. doi:10.1016/j.jval.2026.01.010

BibTeX
@article{Hoshi2026,
  author = {Hoshi, Shu-Ling and Seposo, Xerxes and Kondo, Masahide},
  title = {Economic impact of RSV prefusion F protein-based (RSVpreF) vaccination and nirsevimab prophylaxis on RSV-associated disease among Japanese infants},
  journal = {Value in Health},
  year = {2026},
  doi = {10.1016/j.jval.2026.01.010}
}
Kostenlos starten →